McLean Asset Management Corp Has $370,000 Position in Lam Research Co. (NASDAQ:LRCX)

McLean Asset Management Corp boosted its stake in shares of Lam Research Co. (NASDAQ:LRCX) by 6.3% during the 4th quarter, Holdings Channel reports. The institutional investor owned 5,122 shares of the semiconductor company’s stock after buying an additional 302 shares during the quarter. McLean Asset Management Corp’s holdings in Lam Research were worth $370,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Atwood & Palmer Inc. bought a new position in shares of Lam Research in the 4th quarter worth about $27,000. West Oak Capital LLC raised its position in shares of Lam Research by 50.9% in the 4th quarter. West Oak Capital LLC now owns 400 shares of the semiconductor company’s stock worth $29,000 after acquiring an additional 135 shares in the last quarter. Finley Financial LLC bought a new position in shares of Lam Research in the 4th quarter worth about $30,000. Householder Group Estate & Retirement Specialist LLC raised its position in shares of Lam Research by 159.1% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 500 shares of the semiconductor company’s stock worth $36,000 after acquiring an additional 307 shares in the last quarter. Finally, Laurel Wealth Advisors LLC bought a new position in shares of Lam Research in the 4th quarter worth about $37,000. 84.61% of the stock is owned by institutional investors and hedge funds.

Lam Research Price Performance

Shares of NASDAQ LRCX opened at $79.68 on Monday. Lam Research Co. has a twelve month low of $68.87 and a twelve month high of $113.00. The stock’s 50 day moving average price is $75.43 and its 200-day moving average price is $79.63. The company has a market capitalization of $102.52 billion, a PE ratio of 25.75, a PEG ratio of 1.53 and a beta of 1.45. The company has a quick ratio of 1.74, a current ratio of 2.53 and a debt-to-equity ratio of 0.53.

Lam Research Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, January 8th. Investors of record on Wednesday, December 11th were paid a $0.23 dividend. The ex-dividend date of this dividend was Wednesday, December 11th. This represents a $0.92 annualized dividend and a yield of 1.15%. Lam Research’s payout ratio is 29.74%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Morgan Stanley boosted their target price on Lam Research from $76.00 to $78.00 and gave the company an “equal weight” rating in a research report on Thursday, December 5th. B. Riley decreased their target price on Lam Research from $132.50 to $105.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $100.00 target price on shares of Lam Research in a research report on Thursday, October 24th. KeyCorp raised Lam Research from a “sector weight” rating to an “overweight” rating and set a $95.00 target price for the company in a research report on Friday, January 17th. Finally, Wolfe Research lowered Lam Research from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, January 15th. Nine research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Lam Research currently has a consensus rating of “Moderate Buy” and a consensus price target of $95.77.

About Lam Research

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.